探讨紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床疗效

Venously and abdominally giving paclitaxel and cisplatin in treatment of advanced ovarian cancer

目的总结紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床疗效。方法将2014年1至12月在本院人院治疗的72例晚期卵巢癌患者纳入本组研究中，按照给药方式的不同将72例患者分为双途径组（n=36）与常规组（n=36），常规组采用常规静脉给药法，双途径组使用紫杉醇联合顺铂腹腔和静脉双途径疗法，统计两组疗效及3年总生存率。结果在肿瘤变化、腹水控制、CA125指标变化与治疗有效率上，双途径组疗效更为理想，上述数据组间比较差异均有统计学意义（均P〈0．05）；针对患者进行随访，随访截止时间为2016年12月，观察患者的3年生存率，双途径组的3年生存率为50．0％，常规组的3年生存率为27．8％，经Log—rank检验对比，两组患者的3年总生存率差异有统计学意义（Log—rank=4．278，P=0．039）。结论对于晚期卵巢癌患者，紫杉醇联合顺铂腹腔和静脉双途径疗法行之有效，可以有效控制患者腹水、缩小肿瘤直径，临床疗效理想，并能有效地改善患者的预后。

Objective To summarize the clinical effect of venously and abdominally giving paclitaxel combining cisplatin in treatment of advanced ovarian cancer. Methods 72 patients with advanced ovarian cancer treated at our hospital from January, 2014 to December, 2014 were selected as the study objects and were divided into a dual-way group and a routine group according to the different methods of drug delivery. The routine group were venously given paclitaxel and cisplatin and the dual-way group venously and abdominally. The treatment effect and 3-year survival rate were compared between these two groups. Results The tumor change, ascites control, CA125, and treatment efficacy were better in the dual-way group than in the routine group, with statistical differences （all P 〈 0.05）. The patients were followed up to December, 2016 and the 3-year survival rate was 50.0% in the dual-way group and was 27.8% in the routine group, with a statistical difference （Log-rank=4.278, P=0.039）. Conclusion Venously and abdominally giving paclitaxel and cisplatin in the treatment of patients with advanced ovarian cancer is effective and can effectively control ascites, shrink the tumor diameter, and effectively improve the patients＇ prognosis.